Leto, Simonetta M.

Effective drug combinations in breast, colon and pancreatic cancer cells

Jaaks, P., Coker, E. A., Vis, D. J., Edwards, O., Carpenter, E. F., Leto, S. M., Dwane, L., Sassi, F., Lightfoot, H., Barthorpe, S., et al. (2022) · Nature

Computational Drug Discovery MethodsCancer Genomics and Diagnostics

Cited by 469

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 302

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., et al. (2015) · Science Translational Medicine

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 117

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies

Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 87

Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer

Rizzo, G., Bertotti, A., Leto, S. M., & Vetrano, S. (2021) · Journal of Experimental & Clinical Cancer Research

Cancer Cells and MetastasisColorectal Cancer Treatments and Studies

Cited by 51